Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer

A total of 16 premenopausal women with metastatic breast cancer (N=13) or locally advanced primary breast cancer (N=3) were treated with a combination of a gonadotropin-releasing hormone agonist goserelin, and a selective aromatase inhibitor anastrozole. All had previously been treated with gosereli...

Descripción completa

Detalles Bibliográficos
Autores principales: Forward, D P, Cheung, K L, Jackson, L, Robertson, J F R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409605/
https://www.ncbi.nlm.nih.gov/pubmed/14760369
http://dx.doi.org/10.1038/sj.bjc.6601557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409605/
https://www.ncbi.nlm.nih.gov/pubmed/14760369
http://dx.doi.org/10.1038/sj.bjc.6601557

Ejemplares similares